Insights and Analysis
Court of Appeal grants Mylan stay of injunction pending appeal against validity of Neurim divisional
Registered Content
05 April 2022
Daniel Brook
PartnerLondon
Email [email protected]hoganlovells.com
Phone +44 20 7296 5484
Fax +44 20 7296 2001
LanguagesEnglish
Practice groupIntellectual Property, Media, and Technology
"Daniel Brook is ‘technically very competent’ and ‘gets the ins and outs of even the most complex piece of patent litigation’".
Legal 500, 2018
Daniel is a patent litigator in the UK. He acts for clients such as MSD, Lilly, Amgen and BMS. Recent key cases include Actavis v Lilly (Supreme Court), Schutz v Werit (Supreme Court), and BMS v Teva (availability of interim injunctions).
He has experience with each of the major patent jurisdictions in Europe. He regularly manages cross border patent litigation for clients on their most important products and has been involved in a number of leading cases.
Daniel is ranked by Chambers UK - 'Clients commend his 'high-quality counselling' and his 'clear, well-structured' communications.', Legal 500, MIP IP Stars, IAM Patent 1000 and Who's Who Legal.
Awards and recognitions
2018
Hot 100
The Lawyer
2017-2018
Intellectual Property: Patent Litigation (UK)
Chambers Global
2018
Impact Case of the Year
Managing Intellectual Property Awards
2014 - 2018
Intellectual Property: Patent Litigation
Chambers UK
2013 - 2018
Pharmaceuticals and biotechnology
Legal 500
2013 - 2018
Intellectual Property
Legal 500
2013 - 2018
IAM Patent 1000
2017 - 2018
Patents
IP Star
2018
Patents
Who's Who Legal
Education and admissions
Education
M.A. Natural Sciences - Chemistry, University of Cambridge, 1999
M.Sci, University of Cambridge, 1999
Memberships
AIPPI Council Member
CIPA
EPLAW
Representative experience
Acting for MSD in relation to patent challenges around its products including simvastatin, lovastatin, alendronate and raltegravir.
Acting for Lilly in relation to patent challenges around its oncology products including pemetrexed (Supreme Court) and gemcitabine.
Acting for BMS in relation to patent challenges around its products, dasatinib, efavirenz and atazanavir.
Acting for a number of electronic clients including HTC, ZTE and BlackBerry on European patent litigation matters.
Latest thinking and events
Court of Appeal grants Mylan stay of injunction pending appeal against validity of Neurim divisional
Webinar
Select IP with Hogan Lovells | Webinar no. 12: Patent Litigation: Use of experts
10 March 2022 | 3:00 PM - 4:30 PM (JST)
Published Works
Patent Litigation 2021 guide Chambers and Partners
15 February 2021
Press Releases
Eli Lilly secures major win in its long-running patent dispute with Fresenius Kabi over oncology drug Alimta
16 September 2020
Insights and Analysis
UK Supreme Court hands down eagerly awaited FRAND issues ruling in Unwired Planet
Registered Content
27 August 2020
Insights and Analysis
UK Court of Appeal rules no interim injunction in patent case
Registered Content
25 June 2020
